Intragenic ERBB2 kinase mutations in tumours

Philip Stephens; Marco A. Pierotti; Kristian Gray; Katy Hills; Ken Edwards; Chris Hunter; Chris Greenman; Keiran Raine; Leendert H. J. Looijenga; Richard Lugg; Matthew J. Blow; David N. Louis; Bruce Malkowicz; Adrian G. Parker; Sara Widaa; Kelly Halliday; Vivienne Kosmidou; Lewis Ratford; Anja Drozd; Oliver B. Clarke; Adrienne M. Flanagan; Jennifer Varian; Ed Dicks; Raffaella Smith; Yvonne Stephens; Rebecca Shepherd; Andy Barthorpe; Andrew Yates; Graham R. Bignell; Margaret A. Knowles; Suet Yi Leung; Janet Perry; Rebecca R. Foster; Robert Petty; Helen Davies; Angus Dike; Lisa Brackenbury; Jennifer Cole; Colin S. Cooper; Jon W. Teague; Francis Brasseur; Alexandra Small; Andy Menzies; Sofie West; Simon Forbes; Claire Stevens; Adam P. Butler; Sarah O’Meara; Calli Tofts; Sarah Edkins

doi:10.1038/431525b

Intragenic ERBB2 kinase mutations in tumours

Philip Stephens(Wellcome Sanger Institute), Marco A. Pierotti(Società Italiana di Nefrologia), Kristian Gray(Wellcome Sanger Institute), Katy Hills(Wellcome Sanger Institute), Ken Edwards(Wellcome Sanger Institute), Chris Hunter(Wellcome Sanger Institute), Chris Greenman(University of East Anglia), Keiran Raine(Wellcome Sanger Institute), Leendert H. J. Looijenga(University Medical Center Utrecht), Richard Lugg(Wellcome Sanger Institute), Matthew J. Blow(Wellcome Sanger Institute), David N. Louis(Brigham and Women's Hospital), Bruce Malkowicz(University of Pennsylvania), Adrian G. Parker(Wellcome Sanger Institute), Sara Widaa(Wellcome Sanger Institute), Kelly Halliday(Wellcome Sanger Institute), Vivienne Kosmidou(Wellcome Sanger Institute), Lewis Ratford(Wellcome Sanger Institute), Anja Drozd(Wellcome Sanger Institute), Oliver B. Clarke(Columbia University Irving Medical Center), Adrienne M. Flanagan(Royal National Orthopaedic Hospital), Jennifer Varian(Wellcome Sanger Institute), Ed Dicks(Institute of Cancer Research), Raffaella Smith(Wellcome Sanger Institute), Yvonne Stephens(Wellcome Sanger Institute), Rebecca Shepherd(Lancaster University), Andy Barthorpe(Wellcome Sanger Institute), Andrew Yates(European Bioinformatics Institute), Graham R. Bignell(Lund University), Margaret A. Knowles(St James's University Hospital), Suet Yi Leung(Tuen Mun Hospital), Janet Perry(Wellcome Sanger Institute), Rebecca R. Foster(University of Bristol), Robert Petty(Wellcome Sanger Institute), Helen Davies(German Cancer Research Center), Angus Dike(Wellcome Sanger Institute), Lisa Brackenbury(Wellcome Sanger Institute), Jennifer Cole(Wellcome Sanger Institute), Colin S. Cooper(University of East Anglia), Jon W. Teague(Wellcome Sanger Institute), Francis Brasseur(Ludwig Cancer Research), Alexandra Small(Wellcome Sanger Institute), Andy Menzies(Wellcome Sanger Institute), Sofie West(Wellcome Sanger Institute), Simon Forbes(Wellcome Sanger Institute), Claire Stevens(Wellcome Sanger Institute), Adam P. Butler(Wellcome Sanger Institute), Sarah O’Meara(Wellcome Sanger Institute), Calli Tofts(Wellcome Sanger Institute), Sarah Edkins(Wellcome Sanger Institute)

Nature

September 1, 2004

10.1038/431525b

Cited by 790

Related Papers

Mutations of the BRAF gene in human cancer

|Nature|2002|10.7k

Signatures of mutational processes in human cancer

|Nature|2013|10.1k

COSMIC: the Catalogue Of Somatic Mutations In Cancer

|Nucleic Acids Research|2018|5.2k

The 2007 WHO Classification of Tumours of the Central Nervous System

|Acta Neuropathologica|2007|4.6k

Genomic Classification and Prognosis in Acute Myeloid Leukemia

|New England Journal of Medicine|2016|4.4k